[go: up one dir, main page]

AU1320095A - Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent - Google Patents

Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent

Info

Publication number
AU1320095A
AU1320095A AU13200/95A AU1320095A AU1320095A AU 1320095 A AU1320095 A AU 1320095A AU 13200/95 A AU13200/95 A AU 13200/95A AU 1320095 A AU1320095 A AU 1320095A AU 1320095 A AU1320095 A AU 1320095A
Authority
AU
Australia
Prior art keywords
dibenzazepines
antiepileptic agent
solubilisation
aqueous
cyclodextrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU13200/95A
Other versions
AU680708B2 (en
Inventor
Florence Djedaini-Pilard
Bruno Perly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Publication of AU1320095A publication Critical patent/AU1320095A/en
Application granted granted Critical
Publication of AU680708B2 publication Critical patent/AU680708B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU13200/95A 1993-12-22 1994-12-21 Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent Ceased AU680708B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9315471 1993-12-22
FR9315471A FR2713934B1 (en) 1993-12-22 1993-12-22 Use of amino cyclodextrins for the aqueous solubilization of hydrophobic compounds, in particular of pharmaceutically active molecules.
PCT/FR1994/001503 WO1995017191A1 (en) 1993-12-22 1994-12-21 Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent.

Publications (2)

Publication Number Publication Date
AU1320095A true AU1320095A (en) 1995-07-10
AU680708B2 AU680708B2 (en) 1997-08-07

Family

ID=9454243

Family Applications (1)

Application Number Title Priority Date Filing Date
AU13200/95A Ceased AU680708B2 (en) 1993-12-22 1994-12-21 Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent

Country Status (7)

Country Link
EP (1) EP0735879B1 (en)
JP (1) JPH09506889A (en)
AU (1) AU680708B2 (en)
DE (1) DE69432268T2 (en)
FR (1) FR2713934B1 (en)
HU (1) HU219606B (en)
WO (1) WO1995017191A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444090A1 (en) 2005-09-30 2012-04-25 Lundbeck Inc. Novel parenteral carbamazepine formulation
US9629797B2 (en) 2005-09-30 2017-04-25 Lundbeck Pharmaceuticals Llc Parenteral carbamazepine formulation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828311B2 (en) 2002-05-29 2004-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Formulation for the parenteral application of a sodium channel blocker
DE10223783A1 (en) * 2002-05-29 2003-12-11 Boehringer Ingelheim Pharma New formulation for parenteral administration of a Na-channel blocker
JP2007538112A (en) 2004-01-29 2007-12-27 ピナクル ファーマシューティカルズ β-cyclodextrin derivatives and their use against anthrax lethal toxin
WO2006083678A2 (en) 2005-01-28 2006-08-10 Pinnacle Pharmaceuticals, Inc. β-CYCLODEXTRIN DERIVATIVES AS ANTIBACTERIAL AGENTS
AU2013200204B9 (en) * 2005-09-30 2015-03-05 Lundbeck Llc Novel parenteral carbamazepine formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY106598A (en) * 1988-08-31 1995-06-30 Australian Commercial Res & Development Ltd Compositions and methods for drug delivery and chromatography.
EP0491812A4 (en) * 1989-09-14 1992-11-04 Australian Commercial Research & Development Limited Drug delivery compositions
EP0435826A1 (en) * 1989-12-27 1991-07-03 Ciba-Geigy Ag Intravenous solutions for epilepsy
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2444090A1 (en) 2005-09-30 2012-04-25 Lundbeck Inc. Novel parenteral carbamazepine formulation
US9629797B2 (en) 2005-09-30 2017-04-25 Lundbeck Pharmaceuticals Llc Parenteral carbamazepine formulation
US9770407B2 (en) 2005-09-30 2017-09-26 Lundbeck Pharmaceuticals Llc Parenteral carbamazepine formulation

Also Published As

Publication number Publication date
AU680708B2 (en) 1997-08-07
HU9601737D0 (en) 1996-08-28
JPH09506889A (en) 1997-07-08
HUT75333A (en) 1997-05-28
WO1995017191A1 (en) 1995-06-29
DE69432268D1 (en) 2003-04-17
HU219606B (en) 2001-05-28
FR2713934B1 (en) 1996-01-12
FR2713934A1 (en) 1995-06-23
DE69432268T2 (en) 2003-12-04
EP0735879B1 (en) 2003-03-12
EP0735879A1 (en) 1996-10-09

Similar Documents

Publication Publication Date Title
AU3951699A (en) The use of an anti-microbial compound for disinfection
AU1176995A (en) Taxol formulation
AU6020494A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
AU5718596A (en) Sonicated dextrose-albumin ultrasound contrast agent, contai ning perfluorobutane
AU4553396A (en) Aqueous paint composition
AU2225397A (en) Azolobenzazepine derivatives as neurologically active agents
AU5121298A (en) Aqueous cleansing composition
AU6641396A (en) Dehalogenation of halogenated hydrocarbons in aqueous compositions
AU1246995A (en) Alpha-quaternary-alpha-amino acids for use as cns agents
AU696367B2 (en) Aqueous textile treatment compositions containing an ultra- violet absorbing agent
AU5563298A (en) Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours
AU7168798A (en) Cleaning compostions containing biostatic agent
AU4797596A (en) Use of hydrofluoroalkenes as cleaning agents, and compositions which may be used for their purpose
AU1166097A (en) Indoloquinone derivatives as bioreductive agents
AU2448895A (en) Device for the release of an active agent
AU1320095A (en) Use of amino cyclodextrins for the aqueous solubilisation of dibenzazepines for use as an antiepileptic agent
AU5322998A (en) Use of mixtures of active substances for the production of hypocholesteremic agents
AU6413996A (en) Mr contrast agent
AU1354199A (en) Process for the preparation of urea
AU4563093A (en) Echographic contrast agent composition
AU6544294A (en) Polystyrene-dissolving agent
AU3814599A (en) Use of erythropoietin for the treatment of haemochromatoses
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AU6597396A (en) Novel 3-amido-triiodophenyl esters as x-ray contrast agents
AU8162994A (en) Aqueous coating composition